Publications by authors named "Craig Shering"

Claim this Profile
P
Phase 1, randomized trials of MEDI1341: cerebrospinal fluid free α-synuclein lowered by >50.
Craig Shering, Michael Pomfret, Robert J Kubiak, Isabelle J Pouliquen, Wei Yin

Brain Commun· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AI-guided patient stratification improves outcomes and efficiency in the AMARANTH Alzheimer's Disease clinical trial.
Delshad Vaghari, Gayathri Mohankumar, Keith Tan, Andrew Lowe, Craig Shering

Nat Commun· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MEDI1814 selectively reduces free Aβ42 in cerebrospinal fluid of non-clinical species and Alzheimer's disease patients.
Christopher Lloyd, Per-Ola Freskgård, Philip Newton, David Lowne, Adrian Nickson, Craig Shering

Alzheimers Dement· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Complementary pre-screening strategies to uncover hidden prodromal and mild Alzheimer's disease: Results from the MOPEAD project.
Mercè Boada, Adrián Rodrigo, Frank Jessen, Bengt Wimblad, Milica G Kramberger, Craig Shering

Alzheimers Dement· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lanabecestat: Neuroimaging results in early symptomatic Alzheimer's disease.
Jennifer A Zimmer, Sergey Shcherbinin, Michael D Devous, Sonja M Bragg, Katherine J Selzler, Craig Shering

Alzheimers Dement (N Y)· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease.
Alette M Wessels, Christopher Lines, Robert A Stern, James Kost, Tiffini Voss, Craig Shering

Alzheimers Dement· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials.
Alette M Wessels, Pierre N Tariot, Jennifer A Zimmer, Katherine J Selzler, Sonja M Bragg, Craig Shering

JAMA Neurol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The MOPEAD project: Advancing patient engagement for the detection of "hidden" undiagnosed cases of Alzheimer's disease in the community.
Octavio Rodríguez-Gómez, Adrián Rodrigo, Fátima Iradier, Miguel A Santos-Santos, Hans Hundemer, Craig Shering

Alzheimers Dement· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis